Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Plastic and Reconstructive Surgery. Global Open|April 17, 2015
Thoracic outlet syndrome following breast implant ruptureRaakhi Mistry, Yugesh Caplash, Pratyush Giri, et al.
Respirology Case Reports|November 16, 2020
Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine-rituximabThomas Crowhurst, Pratyush Giri, Caroline Smith, et al.
Current Drug Safety|April 30, 2025
Safety Reporting for Auxiliary Medicinal Products in the Sibeprenlimab Phase-III Study According to the New European Union (536/2014) CT RegulationRetesh Kumar, Pratyush Giri, Mai Huang, et al.
The Medical Journal of Australia|January 20, 2012
Outcomes of lymphoma in South Australia, 1977-2007Brendon J Kearney, Luen Bik To, Daniel J Kearney, et al.
Leukemia & Lymphoma|August 4, 2017
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphomaWojciech Jurczak, Sundra Ramanathan, Pratyush Giri, et al.
BMC Cancer|April 11, 2025
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME studyAnna Li, Sam P Costello, Robert V Bryant, et al.
The Lancet. Haematology|July 18, 2017
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled studyWojciech Jurczak, Ilídia Moreira, Govind Babu Kanakasetty, et al.
Internal Medicine Journal|May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman diseaseDipti Talaulikar, Jun Yen Ng, Adam Bryant, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
Pageof 3